



Universiteit  
Leiden

The Netherlands

## **Autoimmunity at the neuromuscular synapse: pathophysiology and disease course**

Lipka, A.F.

### **Citation**

Lipka, A. F. (2021, December 15). *Autoimmunity at the neuromuscular synapse: pathophysiology and disease course*. Retrieved from <https://hdl.handle.net/1887/3246848>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3246848>

**Note:** To cite this publication please use the final published version (if applicable).

# **Autoimmunity at the neuromuscular synapse: pathophysiology and disease course**

Alexander Frederik Lipka

ISBN: 9789464235067

© 2021 Alexander Lipka

Cover design: Figure by Alexander F. Lipka; Layout by Proefschriftmaken.nl

Layout and printed by: Proefschriftmaken.nl

Copyright of published material in Chapters 1-7 lies with the publisher of the journal listed at the beginning of each chapter. No part of this thesis may be reproduced in any form, by print, photocopy, digital file, internet, or any other means without written permission of the copyright holder.

# **Autoimmunity at the neuromuscular synapse: pathophysiology and disease course**

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,

op gezag van rector magnificus prof.dr.ir. H. Bijl,

volgens besluit van het college voor promoties

te verdedigen op woensdag 15 december 2021

klokke 16.15 uur

door

Alexander Frederik Lipka

Geboren te Leidschendam

In 1983

**Promotor:**

Prof. dr. J.J.G.M. Verschuuren

**Co-promotores:**

Dr. M. J. Titulaer, Erasmus MC

Dr. M.G.M. Huijbers

**Promotiecommissie:**

Prof. dr. P.S. Hiemstra

Prof. dr. B.G.M. van Engelen, Radboud UMC

Dr. A.J. van der Kooi, Amsterdam UMC





## Table of contents

<b>PART I</b>	<b>Lambert-Eaton myasthenic syndrome</b>	<b>9</b>
<b>CHAPTER 1</b>	Introduction and aims <i>Book chapter in: Mazia C (Ed.), Miastenia Gravis y Trastornos Relacionados. Inter-Médica, Buenos Aires, Argentina; 2017. p209-224</i>	11
<b>CHAPTER 2</b>	Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome <i>Hum Immunol 2013 Jul;74(7):849-51</i>	41
<b>CHAPTER 3</b>	SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma <i>Ann N Y Acad Sci. 2012 Dec;1275(1): 70-7</i>	51
<b>CHAPTER 4</b>	Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome <i>Neurology. 2020 Feb 4;94(5):e511-e520</i>	67
<b>CHAPTER 5</b>	Lowering the cut-off value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome <i>Muscle &amp; Nerve, 2020 Jul;62(1):111-114</i>	91
<b>PART II</b>	<b>Myasthenia gravis</b>	<b>101</b>
<b>CHAPTER 6</b>	Initial compound muscle action potential amplitude is a marker for disease severity in myasthenia gravis <i>submitted</i>	103
<b>CHAPTER 7</b>	Ephedrine treatment for autoimmune myasthenia gravis <i>Neuromuscul Disord. 2017 Mar;27(3):259-265</i>	115
<b>CHAPTER 8</b>	Discussion and future perspectives	131
<b>Addendum</b>		
	Samenvatting en discussie	151
	List of publications	165
	Dankwoord	167
	Curriculum vitae	169